David C. Oxley

Direttore/Membro del Consiglio presso TB Biosciences, Inc.

Health Technology

Health Services

Profilo

David C.
Oxley is currently a Non-Executive Director at TB Biosciences, Inc. He previously held the position of Executive VP-Worldwide Sales & Marketing at Trinity Biotech Plc and Vice President-Emerging Market Sales at Plus Therapeutics, Inc. He will also serve as the President-International at Exopharm Ltd.
from 2021 to 2023.

Posizioni attive di David C. Oxley

Società	Posizione	Inizio
TB Biosciences, Inc. TB Biosciences, Inc. Medical/Nursing ServicesHealth Services TB Biosciences, Inc. operates as a early stage development medical diagnostics company which develops a rapid point-of-care tuberculosis tests. It uses key peptides to detect antibodies in patients with active tuberculosis derived from the genome of the tuberculosis organism, thus offering a completely new approach to testing. The firm is using an array of patented peptides developed and exclusively licensed from the New York university school of medicine. The company was founded by Daniel Malamud, Susan Zolla-Pazner, Suman Laal, R. Sam Niedbala and William Abrams in May 2013 and is headquartered in Bethlehem, PA.	Direttore/Membro del Consiglio	01/08/2013

Tutte le posizioni attive di David C. Oxley

Precedenti posizioni note di David C. Oxley

Società	Posizione	Fine
EXOPHARM	Presidente	01/01/2023
TRINITY BIOTECH PLC	Vendite & Marketing	-
PLUS THERAPEUTICS, INC.	Vendite & Marketing	-

Vedi nel dettaglio l'esperienza di David C. Oxley

Esperienze
Posizioni ricoperte

Attive

Inattive

Società quotate in Borsa

Aziende private

Vedi nel dettaglio l'esperienza di David C. Oxley

Relazioni

Relazioni di 1° grado

Aziende connesse in 1º grado

Uomo

Donna

Amministratori

Dirigenti

Vedi i contatti personali

Società collegate

Società quotate in Borsa	2
PLUS THERAPEUTICS, INC.	Health Technology
TRINITY BIOTECH PLC	Health Technology

Aziende private	2
TB Biosciences, Inc. TB Biosciences, Inc. Medical/Nursing ServicesHealth Services TB Biosciences, Inc. operates as a early stage development medical diagnostics company which develops a rapid point-of-care tuberculosis tests. It uses key peptides to detect antibodies in patients with active tuberculosis derived from the genome of the tuberculosis organism, thus offering a completely new approach to testing. The firm is using an array of patented peptides developed and exclusively licensed from the New York university school of medicine. The company was founded by Daniel Malamud, Susan Zolla-Pazner, Suman Laal, R. Sam Niedbala and William Abrams in May 2013 and is headquartered in Bethlehem, PA.	Health Services
Exopharm Ltd. Exopharm Ltd. Pharmaceuticals: MajorHealth Technology Exopharm Ltd. engages in the research and development of biopharmaceutical drugs. The company was founded by Ian Dixon and Gregor Lichtfuss in 2013 and is headquartered in Camberwell, Australia.	Health Technology